AGIOS PHARMACEUTICALS INC (AGIO)
Sector: Health Care
2026 Annual Meeting Analysis
AGIOS PHARMACEUTICALS INC · Meeting: June 18, 2026
Directors FOR
2
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Ms. Smith currently sits on the boards of Akebia Therapeutics, Protara Therapeutics, Spero Therapeutics, and Tvardi Therapeutics in addition to Agios — a total of five public company board seats; our policy requires a vote against any non-executive director who holds four or more public board seats because that level of commitment raises serious concerns about whether any single company's shareholders receive adequate attention and engagement.
For Analysis
Dr. Ballal joined the board in August 2022 (less than 4 years ago) and the 3-year TSR peer gap of -13.9pp does not exceed the 35pp threshold required to trigger a vote against; no overboarding, independence, attendance, or other disqualifying flags are present, and he brings relevant biotechnology executive and investment experience.
Mr. Goff joined the board in August 2022; as an executive director he is subject to the TSR trigger, but the 3-year stock return gap versus the company-disclosed peer group median is only -13.9pp, well below the 35pp threshold needed to fire a vote against, so no TSR concern applies; his extensive rare-disease commercial leadership experience is directly relevant to Agios's strategy.
Two of the three Class I nominees receive a FOR vote. Dr. Ballal and Mr. Goff both joined in August 2022, have relevant qualifications, and the company's 3-year TSR underperformance versus its disclosed peer group (-13.9pp) falls well below the 35pp trigger threshold. Ms. Smith is opposed solely due to overboarding — she holds five simultaneous public company board seats, which exceeds the four-seat maximum under our policy.
Say on Pay
✓ FORCEO
Brian Goff
Total Comp
$5,370,389
Prior Support
94%%
The prior year say-on-pay vote received approximately 94% support, well above the 70% threshold that would require visible remediation. CEO Brian Goff's total compensation of $5,370,389 is consistent with market expectations for a CEO at a $1.5 billion biotech company, and the company states that 89% of Mr. Goff's total direct pay is variable and performance-linked (including stock options, restricted stock awards, and performance stock awards tied to corporate milestones), which satisfies the policy requirement that at least 50-60% of pay be at-risk. The company also maintains a clawback policy and uses an independent compensation consultant, and the 3-year peer group TSR gap of -13.9pp does not rise to the level that would flag misalignment between incentive pay and shareholder outcomes.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
9 yrs
Audit Fees
$1,604,000
Non-Audit Fees
$197,125
PwC has served as Agios's auditor since May 2017 (approximately 9 years), well below the 25-year tenure threshold; non-audit fees of $197,125 (audit-related fees of $195,000 plus other fees of $2,125) represent about 12% of audit fees of $1,604,000, comfortably within the 50% limit; PwC is a Big 4 firm appropriate for a $1.5 billion market cap company; no material restatements or other disqualifying concerns were identified.
Overall Assessment
The 2026 Agios annual meeting presents four proposals: the board recommends supporting all of them, but our policy diverges on one director. We vote FOR on two of the three Class I director nominees (Dr. Ballal and Mr. Goff), vote AGAINST Ms. Smith due to overboarding across five simultaneous public company boards, vote FOR on the auditor (PwC, reasonable fees, short tenure, Big 4 firm), and vote FOR on say-on-pay given strong prior-year support, a largely performance-based pay structure, and CEO compensation that appears consistent with the company's size and peer group. The equity plan amendment (Proposal 3) falls outside current policy coverage and is noted without a vote determination.
Compensation Peer Group
14 companies disclosed in 2026 proxy filing